Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Arhaus
ARHS
$1.33B
| $747K | ﹤0.01% |
+63,003
| New | +$594K |
|
2577
UNIFI
UFI
$132M
| $745K | ﹤0.01% |
111,934
+70,100
| +168% | +$457K |
|
2578
National Bankshares
NKSH
$269M
| $743K | ﹤0.01% |
22,970
-1,900
| -8% | -$51.1K |
|
2579
Axogen
AXGN
$2.4B
| $742K | ﹤0.01% |
+108,600
| New | +$604K |
|
2580
PRA Group
PRAA
$788M
| $739K | ﹤0.01% |
28,197
-103,014
| -79% | -$1.93M |
|
|
LOAN
2581
Manhattan Bridge Capital
LOAN
$47.3M
| $738K | ﹤0.01% |
148,528
+30,600
| +26% | +$143K |
|
2582
Invesco S&P 500 High Beta ETF
SPHB
$1.02B
| $733K | ﹤0.01% |
+8,900
| New | +$641K |
|
2583
PCB Bancorp
PCB
$391M
| $732K | ﹤0.01% |
39,701
+3,400
| +9% | +$55K |
|
|
SNT
2584
Senstar Technologies
SNT
$42M
| $732K | ﹤0.01% |
567,609
+2,693
| +0.5% | +$3.22K |
|
2585
Trevi Therapeutics
TRVI
$2.58B
| $727K | ﹤0.01% |
542,700
+475,400
| +706% | +$720K |
|
2586
Kingstone Companies
KINS
$289M
| $726K | ﹤0.01% |
340,776
-8,813
| -3% | -$19.5K |
|
|
AC
2587
DELISTED
Associated Capital Group
AC
| $725K | ﹤0.01% |
20,303
+3,103
| +18% | +$106K |
|
2588
Flexible Solutions
FSI
$64.6M
| $719K | ﹤0.01% |
376,445
-3,800
| -1% | -$7.26K |
|
2589
Capricor Therapeutics
CAPR
$243M
| $716K | ﹤0.01% |
146,321
+103,700
| +243% | +$338K |
|
2590
Scholastic
SCHL
$777M
| $716K | ﹤0.01% |
19,001
-6,019
| -24% | -$230K |
|
2591
Bristow Group
VTOL
$1.36B
| $715K | ﹤0.01% |
25,300
+1,500
| +6% | +$40.5K |
|
2592
Bioventus
BVS
$1.16B
| $713K | ﹤0.01% |
135,245
+55,445
| +69% | +$219K |
|
2593
KVH Industries
KVHI
$160M
| $712K | ﹤0.01% |
135,400
-1,200
| -0.9% | -$5.86K |
|
2594
Edgewise Therapeutics
EWTX
$4.61B
| $708K | ﹤0.01% |
64,700
-86,300
| -57% | -$606K |
|
2595
Weyco Group
WEYS
$434M
| $706K | ﹤0.01% |
22,526
+5,600
| +33% | +$159K |
|
|
LUMO
2596
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $705K | ﹤0.01% |
221,614
-5,100
| -2% | -$17.4K |
|
|
SBDS
2597
DELISTED
Solo Brands Inc
SBDS
| $705K | ﹤0.01% |
2,860
-2,218
| -44% | -$432K |
|
|
OTLY
2598
Oatly Group
OTLY
$438M
| $704K | ﹤0.01% |
29,825
+26,560
| +813% | +$438K |
|
2599
Champions Oncology
CSBR
$72.7M
| $701K | ﹤0.01% |
124,791
-1,000
| -0.8% | -$5.58K |
|
2600
Smart Sand
SND
$194M
| $700K | ﹤0.01% |
362,600
+61,944
| +21% | +$126K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.